155877-83-1

Basic information

• Product Name: 4-(7,8,9,10-TETRAHYDRO-5,7,7,10,10-PENTAMETHYL-5H-BENZO[E]NAPHTHO[2,3-B][1,4]DIAZEPIN-13-YL)BENZOIC ACID
• Synonyms: 4-(7,8,9,10-TETRAHYDRO-5,7,7,10,10-PENTAMETHYL-5H-BENZO[E]NAPHTHO[2,3-B][1,4]DIAZEPIN-13-YL)BENZOIC ACID;LE 135;4-(7,8,9,10-Tetrahydro-5,7,7,10,10-pentamethyl-(5H)-benzo[e]naphtho[2.3-b][1.4]diazepine-13-yl)benzoicacid;Benzoic acid, 4-(7,8,9,10-tetrahydro-5,7,7,10,10-pentaMethyl-5H-benzo[e]naphtho[2,3-b][1,4]diazepin-13-yl)-;4-(5,7,7,10,10-Pentamethyl-7,8,9,10-tetrahydro-5H-benzo[e]naphtho[2,3-b][1,4]diazepin-13-yl)benzoic acid
• CAS NO: 155877-83-1
• Molecular Formula: C29H30N2O2
• Molecular Weight: 438.56
• Product Categories: Intracellular receptor
• Mol File: 155877-83-1.mol

Chemical Properties

• Boiling Point: 601.336°C at 760 mmHg
• Flash Point: 317.477°C
• Appearance: yellow to orange/
• Density: 1.176g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.628
• Storage Temp.: Store at +4°C
• Solubility: DMSO: soluble15mg/mL, clear
• PKA: 3.02±0.10(Predicted)
• CAS DataBase Reference: 4-(7,8,9,10-TETRAHYDRO-5,7,7,10,10-PENTAMETHYL-5H-BENZO[E]NAPHTHO[2,3-B][1,4]DIAZEPIN-13-YL)BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(7,8,9,10-TETRAHYDRO-5,7,7,10,10-PENTAMETHYL-5H-BENZO[E]NAPHTHO[2,3-B][1,4]DIAZEPIN-13-YL)BENZOIC ACID(155877-83-1)
• EPA Substance Registry System: 4-(7,8,9,10-TETRAHYDRO-5,7,7,10,10-PENTAMETHYL-5H-BENZO[E]NAPHTHO[2,3-B][1,4]DIAZEPIN-13-YL)BENZOIC ACID(155877-83-1)

Safety Data

• Hazard Codes: Xi
• Statements: 36/38
• Safety Statements: 26
• WGK Germany: 3
• Hazardous Substances Data: 155877-83-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(7,8,9,10-TETRAHYDRO-5,7,7,10,10-PENTAMETHYL-5H-BENZO[E]NAPHTHO[2,3-B][1,4]DIAZEPIN-13-YL)BENZOIC ACID is used as a pharmaceutical compound for its potential therapeutic properties. Its specific application reason is not provided in the materials, but given its structural complexity and the known biological activities of related compounds, it may be explored for its potential in treating various medical conditions.
Used in Chemical Research:
4-(7,8,9,10-TETRAHYDRO-5,7,7,10,10-PENTAMETHYL-5H-BENZO[E]NAPHTHO[2,3-B][1,4]DIAZEPIN-13-YL)BENZOIC ACID can be used as a research chemical for studying its chemical properties, reactivity, and potential interactions with other molecules. This may lead to the discovery of new applications or the development of new compounds with improved properties.
Used in In Vitro Islet Treatment:
As mentioned in the provided materials, 4-(7,8,9,10-TETRAHYDRO-5,7,7,10,10-PENTAMETHYL-5H-BENZO[E]NAPHTHO[2,3-B][1,4]DIAZEPIN-13-YL)BENZOIC ACID, also known as LE 135, has been used for in vitro islet treatment. It acts as a retinoic acid receptor (RAR) antagonist, displaying moderate selectivity for RARβ over RARα. LE 135 inhibits retinoic acid-induced transcriptional activation of RARβ, which may have implications for the treatment of certain conditions related to islet function.

Biological Activity

Retinoic acid antagonist; displays moderate selectivity for RAR β over RAR α (Ki values are 0.22 and 1.4 μ M respectively). Highly selective over RAR γ and RXR α . Inhibits human HL-60 leukemia cell differentiation induced by Am80 (IC 50 = 150 nM).

Biochem/physiol Actions

LE135 is a retinoic acid receptor (RAR) antagonist with selectivity for RARβ (Ki = 220 nM) over RARα (Ki = 1.4 μM). LE135 inhibits retinoic acid-induced transcriptional activation of RARβ (>70% inhibition at 10 μM), but not RARα, RARγ or retinoid X receptor α (RXRα). There is high interest in retinoic acid receptors for cancer and for differentiation studies. LE135 has been shown to inhibit retinoid Am80-induced differentiation of human promyelocytic leukemia HL-60 cells with an IC50 value of 0.2 μM. LE135 has been used to study the role of a retinoic acid receptor-β (RARβ) on the differentiation of mesenchymal stem cells, and was found to inhibit the neuronal differentiation promoting effects of all-trans retinoic acid (ATRA) on mesenchymal stem cells.

InChI:InChI=1/C29H30N2O2/c1-28(2)14-15-29(3,4)22-17-25-23(16-21(22)28)30-26(18-10-12-19(13-11-18)27(32)33)20-8-6-7-9-24(20)31(25)5/h6-13,16-17H,14-15H2,1-5H3,(H,32,33)

Upstream product

• 103-84-4 Acetanilid 
• 155877-81-9 methyl 4-<<5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-3-(N-methyl-N-phenylamino)-2-naphthalenyl>carbamoyl>benzoate 
• 155877-80-8 Methyl-phenyl-(5,5,8,8-tetramethyl-3-nitro-5,6,7,8-tetrahydro-naphthalen-2-yl)-amine 
• 155877-75-1 (5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-3-nitro-2-naphthyl)phenylamine 
• 155877-69-3 6-acetamido-7-nitro-1,2,3,4-tetrahydro-1,1,4,4-tetramethylnaphthalene 
• 155877-79-5 N-methyl-N-phenyl-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene-2,3-diamine 
• 155877-70-6 5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-3-nitro-2-naphthylamine 
• 139162-43-9 N-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-acetamide 
• 6223-78-5 2,5-dichloro-2,5-dimethyl hexane 
• 108-86-1 bromobenzene 
• 155877-82-0 4-(5,7,7,10,10-Pentamethyl-7,8,9,10-tetrahydro-5H-5,12-diaza-benzo[4,5]cyclohepta[1,2-b]naphthalen-13-yl)-benzoic acid methyl ester 

Relevant articles and documents

Retinobenzoic Acids. 6. Retinoid Antagonists with a Heterocyclic Ring

Several candidate retinoid anatgonists were designed on the basis of the ligand superfamily concept and synthesized.Retinoidal activities of these benzimidazole and benzodiazepine derivatives were examined by assay of differentiation-inducing activity on